Consensus Guidance Balances Trauma Survival and Future Reproductive Risks After Transfusion

Henry R, Coleman JR, Holcomb JB, Lammers D, et al. Post-Transfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and Red Blood Cells During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma (ACS-COT), Prehospital Blood Transfusion Coalition (PBTC), National Association of Emergency Medical Services Physicians (NAEMSP), Trauma Hemostasis and Oxygenation Research (THOR) Network, and Allo Hope Foundation (AHF). J Am Coll Surg. July 2026.

Increasing use of low-titer group O whole blood and red blood cells in trauma resuscitation has increased the likelihood that RhD-negative females of childbearing potential (FCPs) will receive RhD-positive blood products. 

Concurrently, national trauma data demonstrate that FCPs with traumatic hemorrhage are approximately 40% less likely to receive low-titer group O whole blood than comparable males, highlighting concerns related to trauma systems and equitable care. Evidence-based guidance for post-transfusion management remains limited.

A multidisciplinary panel representing trauma surgery, transfusion medicine, emergency medicine, critical care, obstetrics, pediatrics, and prehospital care reviewed available literature, registry data, modeling studies, existing guidance, and ethical considerations to develop consensus recommendations through an iterative process for the management of RhD-negative FCPs exposed to RhD-positive blood products during trauma resuscitation.

Reported D-alloimmunization rates following trauma transfusion range from approximately 8%–43%. Modeling studies estimate a perinatal death risk from anti-D-mediated hemolytic disease of the fetus and newborn (HDFN) of approximately 0.04% and a combined severe HDFN/perinatal death risk of approximately 0.24% after RhD-positive transfusion. 

Estimated risk of any HDFN-complicated future pregnancy ranges from approximately 0.6%–6.5%. The panel concluded that RhD-positive blood products should not be withheld when RhD-negative products are unavailable and transfusion is clinically indicated. Recommended management includes selective Rh immunoglobulin prophylaxis for low-volume exposures, structured antibody surveillance, patient counseling, multidisciplinary follow-up, and institutional protocols.

For RhD-negative FCPs with life-threatening hemorrhage, immediate survival should take precedence over potential future reproductive risk. Standardized post-transfusion pathways may support equitable access to life-saving transfusion while mitigating alloimmunization-related reproductive risks.